Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
DRUG: Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution

Sponsor

Bausch & Lomb Incorporated